Epirubicin (Ellence)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 9/15/1999: Initial FDA approval "as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer."

Also known as

Alrubicin Anthracin Binarin Bioepicyna Crisabon E.P.R Elvetium Ellence EPI
EPI Cell Epidoxo Epifil Epilem Epirubicin Epirubicina Microsules Epirubicine Epizin
Epricin Eracin Famorubicin Farmorubicin Farmorubicina Farmorubicine Pharmorubicin CS Riboepi


  1. 1.0 1.1 1.2 Epirubicin (Ellence) package insert
  2. Epirubicin (Ellence) package insert (locally hosted backup)
  3. Epirubicin (Ellence) patient drug information (Chemocare)
  4. Epirubicin (Ellence) patient drug information (UpToDate)